Literature DB >> 26349416

Biology and Treatment of Rhabdoid Tumor.

James I Geller1, Jacquelyn J Roth2, Jaclyn A Biegel3.   

Abstract

Rhabdoid tumor is a rare, highly aggressive malignancy that primarily affects infants and young children. These tumors typically arise in the brain and kidney, although extrarenal, non-central nervous system tumors in almost all soft-tissue sites have been described. SMARCB1 is a member of the SWI/SNF chromatin-remodeling complex and functions as a tumor suppressor in the vast majority of rhabdoid tumors. Patients with germline mutations or deletions affecting SMARCB1 are predisposed to the development of rhabdoid tumors, as well as the genetic disorder schwannomatosis. The current hypothesis is that rhabdoid tumors are driven by epigenetic dysregulation, as opposed to the alteration of a specific biologic pathway. The strategies for novel therapeutic approaches based on what is currently known about rhabdoid tumor biology are presented.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26349416      PMCID: PMC6087667          DOI: 10.1615/critrevoncog.2015013566

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  116 in total

1.  Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.

Authors:  Petar Jelinic; Jennifer J Mueller; Narciso Olvera; Fanny Dao; Sasinya N Scott; Ronak Shah; JianJiong Gao; Nikolaus Schultz; Mithat Gonen; Robert A Soslow; Michael F Berger; Douglas A Levine
Journal:  Nat Genet       Date:  2014-03-23       Impact factor: 38.330

2.  Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors.

Authors:  J A Biegel; J Y Zhou; L B Rorke; C Stenstrom; L M Wainwright; B Fogelgren
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

3.  Loss of SMARCB1/INI1 expression in poorly differentiated chordomas.

Authors:  Bret C Mobley; Jesse K McKenney; Charles D Bangs; Katherine Callahan; Kristen W Yeom; Reinhard Schneppenheim; Melanie G Hayden; Athena M Cherry; Murat Gokden; Michael S B Edwards; Paul G Fisher; Hannes Vogel
Journal:  Acta Neuropathol       Date:  2010-10-30       Impact factor: 17.088

4.  Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system: a multicenter study.

Authors:  Christelle Dufour; Annick Beaugrand; Marie Cécile Le Deley; Franck Bourdeaut; Nicolas André; Pierre Leblond; Anne-Isabelle Bertozzi; Didier Frappaz; Xavier Rialland; Fanny Fouyssac; Christine Edan; Jacques Grill; Marion Quidot; Pascale Varlet
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

5.  Histone deacetylases expression in atypical teratoid rhabdoid tumors.

Authors:  Simone Treiger Sredni; Abby L Halpern; Christopher A Hamm; Maria de Fátima Bonaldo; Tadanori Tomita
Journal:  Childs Nerv Syst       Date:  2012-11-10       Impact factor: 1.475

6.  Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy.

Authors:  Tanya M Tekautz; Christine E Fuller; Susan Blaney; Maryam Fouladi; Alberto Broniscer; Thomas E Merchant; Matthew Krasin; James Dalton; Gregory Hale; Larry E Kun; Dana Wallace; Richard J Gilbertson; Amar Gajjar
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

7.  Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5.

Authors:  Charles W M Roberts; Monique M Leroux; Mark D Fleming; Stuart H Orkin
Journal:  Cancer Cell       Date:  2002-11       Impact factor: 31.743

8.  Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material.

Authors:  Francois Le Loarer; Lei Zhang; Christopher D Fletcher; Agnes Ribeiro; Samuel Singer; Antoine Italiano; Agnes Neuville; Aurélie Houlier; Frederic Chibon; Jean-Michel Coindre; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2014-03-03       Impact factor: 5.006

9.  Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation.

Authors:  Qingyan Liu; Susanna Galli; Ramaprasad Srinivasan; William Marston Linehan; Maria Tsokos; Maria J Merino
Journal:  Am J Surg Pathol       Date:  2013-03       Impact factor: 6.394

10.  Coffin-Siris syndrome is a SWI/SNF complex disorder.

Authors:  Y Tsurusaki; N Okamoto; H Ohashi; S Mizuno; N Matsumoto; Y Makita; M Fukuda; B Isidor; J Perrier; S Aggarwal; A B Dalal; A Al-Kindy; J Liebelt; D Mowat; M Nakashima; H Saitsu; N Miyake; N Matsumoto
Journal:  Clin Genet       Date:  2013-07-23       Impact factor: 4.438

View more
  23 in total

1.  The forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in malignant rhabdoid tumor.

Authors:  Yuichi Shibui; Kenichi Kohashi; Akihiko Tamaki; Izumi Kinoshita; Yuichi Yamada; Hidetaka Yamamoto; Tomoaki Taguchi; Yoshinao Oda
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-21       Impact factor: 4.553

Review 2.  Renal Medullary Carcinoma: Establishing Standards in Practice.

Authors:  Kathryn E Beckermann; Deva Sharma; Shruti Chaturvedi; Pavlos Msaouel; Miguel R Abboud; Yves Allory; Franck Bourdeaut; Julien Calderaro; Aguirre A de Cubas; Vimal K Derebail; Andrew L Hong; Rakhi P Naik; Gabriel G Malouf; Elizabeth A Mullen; Victor E Reuter; Charles W M Roberts; Cheryl L Walker; Christopher G Wood; Michael R DeBaun; Hendrik Van Poppel; Nizar M Tannir; W Kimryn Rathmell
Journal:  J Oncol Pract       Date:  2017-07       Impact factor: 3.840

Review 3.  Atypical teratoid/rhabdoid tumor in adults: a systematic review of the literature with meta-analysis and additional reports of 4 cases.

Authors:  Giuseppe Broggi; Francesca Gianno; Doron Theodore Shemy; Maura Massimino; Claudia Milanaccio; Angela Mastronuzzi; Sabrina Rossi; Antonietta Arcella; Felice Giangaspero; Manila Antonelli
Journal:  J Neurooncol       Date:  2022-02-25       Impact factor: 4.130

4.  Schwannomatosis patient who was followed up for fifteen years: A case report.

Authors:  Kai Li; Si-Jing Liu; Huai-Bo Wang; Chang-Yu Yin; Yong-Sheng Huang; Wei-Tao Guo
Journal:  World J Clin Cases       Date:  2022-07-16       Impact factor: 1.534

5.  Immune-Related LncRNAs as Prognostic Factors for Pediatric Rhabdoid Tumor of the Kidney.

Authors:  Ye Hong; Yi Que; Yang Hu; Bo-Yun Shi; Jia Zhu; Juan Wang; Jun-Ting Huang; Fei-Fei Sun; Lian Zhang; Xin-Ke Zhou; Su-Ying Lu; Yi-Zhuo Zhang
Journal:  Dis Markers       Date:  2022-06-15       Impact factor: 3.464

6.  Cellular, ultrastructural and molecular analyses of epidermal cell development in the planarian Schmidtea mediterranea.

Authors:  Li-Chun Cheng; Kimberly C Tu; Chris W Seidel; Sofia M C Robb; Fengli Guo; Alejandro Sánchez Alvarado
Journal:  Dev Biol       Date:  2017-10-31       Impact factor: 3.582

7.  An analysis of the diagnosis, clinical characteristics, treatment, and survival outcomes of 36 extracranial malignant rhabdoid tumor patients.

Authors:  Yuhua Shan; Jiaoyang Cai; Yali Han; Chenjie Xie; Honxiang Gao; Lei Zhang; Jingjing Li; Ruicheng Tian; Yu Liang; Jing Wang; Changcheng Chen; Bin Ji; Jingyan Tang; Min Xu; Song Gu
Journal:  Transl Pediatr       Date:  2021-06

8.  Case Analysis of 14 Children with Malignant Rhabdoid Tumor of the Kidney.

Authors:  Jing Li; Weiling Zhang; Huimin Hu; Yi Zhang; Yizhuo Wang; Huali Gu; Dongsheng Huang
Journal:  Cancer Manag Res       Date:  2021-06-21       Impact factor: 3.989

9.  Notable Response of SMARCA4-Deficient Undifferentiated Uterine Sarcoma to Palliative Radiation Therapy.

Authors:  Mariko Kurokawa; Takuya Shimizuguchi; Kei Ito; Maki Takao; Toru Motoi; Ayumi Taguchi; Toshiharu Yasugi; Katsuyuki Karasawa
Journal:  Adv Radiat Oncol       Date:  2021-05-25

10.  Polycomb Paralog Chromodomain Inhibitors Active against Both CBX6 and CBX8*.

Authors:  Natalia Milosevich; Chelsea R Wilson; Tyler M Brown; Aktan Alpsoy; Sijie Wang; Katelyn E Connelly; Kirsten A D Sinclair; Felino R Ponio; Rebecca Hof; Emily C Dykhuizen; Fraser Hof
Journal:  ChemMedChem       Date:  2021-07-23       Impact factor: 3.540

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.